EP1663231A1 - Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation - Google Patents

Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation

Info

Publication number
EP1663231A1
EP1663231A1 EP04774524A EP04774524A EP1663231A1 EP 1663231 A1 EP1663231 A1 EP 1663231A1 EP 04774524 A EP04774524 A EP 04774524A EP 04774524 A EP04774524 A EP 04774524A EP 1663231 A1 EP1663231 A1 EP 1663231A1
Authority
EP
European Patent Office
Prior art keywords
composition
itraconazole
surfactant
mixture
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04774524A
Other languages
German (de)
English (en)
Other versions
EP1663231A4 (fr
Inventor
Jong Soo Woo
Hong Gi Samik 2-cha Apt. YI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Priority claimed from PCT/KR2004/002264 external-priority patent/WO2005023262A1/fr
Publication of EP1663231A1 publication Critical patent/EP1663231A1/fr
Publication of EP1663231A4 publication Critical patent/EP1663231A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Definitions

  • the present invention relates to an oral composition of itraconazole having improved itraconazole bioavailability which is not affected by ingested food, and a process for the preparation thereof.
  • Itraconazole a triazole compound
  • Itraconazole a triazole compound
  • bioavailability of orally administered itraconazole is very low because it has an exceedingly low solubility of less than 1 ⁇ g/ml in water and it remains unionized in the gastric juice due to its pKa value of 3.7.
  • degree of bioavailability of orally administered itraconazole varies widely among individuals and depends on other factors such as ingested foods.
  • PCT International Publication No. WO 85/02767 and U.S. Patent No. 4,764,604 teach a method for increasing the solubility of itraconazole by employing a cyclodextrin inclusion compound of itraconazole.
  • PCT International Publication No. WO 94/05263 discloses a coated bead preparation, wherein a core made of pharmaceutically inert or neutral sucrose, dextrine, starch and the like is coated with a mixture of itraconazole and a hydrophilic polymer and, then, the resulting bead is coated again with a polymer, e.g., polyethylene glycol.
  • a coated bead preparation is commercially available from Janssen Pharmaceutica(Beerse, Belgium) under the trade name of Sporanox ® capsule.
  • This solid dispersion is described to have an improved bioavailability of itraconazole which is not influenced by ingested foods, and it is commercially available from Janssen Pharmaceutica(Beerse, Belgium) under the trade name of Sporanox tablet.
  • the manufacturing process of the solid dispersion is hampered by a number of difficulties in controlling various process variables, and the in vivo bioavailability of itraconazole achievable with the above dispersion is still low.
  • Sporanox ® liquid of pH 2 which is prepared by mixing a hydroxypropyl- ⁇ -cyclodextrin inclusion compound of itraconazole, hydrochloric acid, propylene glycol, purified water, sodium hydroxide, sodium saccharin and sorbitol, and is commercially available from Janssen Pharmaceutica(Beerse, Belgium), exhibits a high bioavailability of itraconazole when administered before ingestion, but it has the problems that it must be taken in great quantities due to its low itraconazole concentration of 10 mg/ml, the active ingredient rapidly precipitates when it comes in contact with the intestinal juice, and it is effective only against fungus infection of esophagus. Recently, PCT International Publication No.
  • WO 98/55148 discloses a high viscosity composition
  • a drug which has a very low solubility in water, cyclodextrin, water-soluble acid and a water-soluble organic polymer.
  • this composition has a high viscosity, and accordingly, a large amount of a dispersant is used to lower the viscosity during the capsule making process.
  • the composition exhibits a very low dissolution rate of less than 1% under a neutral or alkaline condition of pH 6.8 or higher.
  • the present inventors suggested a micro-emulsion preconcentrate comprising an antiviral agent which has a very low solubility in water, phosphoric acid, a co-surfactant, a surfactant and an oil in Korean Application No. 2000-83717, and further suggested another micro-emulsion composition modified based on said preconcentrate in Korean Application No. 2001-36930.
  • these compositions still exhibit unsatisfactory itraconazole dissolution rates under a neutral or alkaline condition of pH 6.8 or higher, and thus their bioavailabilities of itraconazole more or less depend on ingested food.
  • a primary object of the present invention to provide an oral composition of itraconazole having improved itraconazole bioavailability which is little influenced by ingested food. It is a further object of the present invention to provide a process for preparing said oral composition.
  • a viscous and glassy composition for oral administration comprising itraconazole, an acidifying agent, an amphiphilic additive, a surfactant and an oil.
  • a method of preparing said composition which comprises the steps of: (a) dissolving itraconazole uniformly in a mixture of the acidifying agent, the amphiphilic additive and a volatile solvent, (b) dissolving the surfactant and the oil in the resulting solution, and (c) removing the volatile solvent therefrom.
  • FIG. 1 shows the respective itraconazole bioavailabilities of the preparations prepared in Example 1 and Comparative Example before and after food ingestion.
  • the inventive composition comprising itraconazole as an active ingredient may be prepared using the other following components: (1) Acidifying agent Representative examples of the acidifying agent which may be used in the present invention to dissolve itraconazole include phosphoric acid, acetic acid, hydrochloric acid, nitric acid, sulfuric acid, citric acid, fumaric acid, maleic acid, and an aqueous solution thereof, wherein 85% phosphoric acid or a diluted solution thereof is preferred.
  • amphiphilic additive which is used in the present invention serves to dissolve itraconazole and adjust the viscosity of the composition to a degree suitable for filling into a capsule.
  • Suitable amphiphilic additives include transcutol(diethyleneglycol monoethyl ether, Gattefosse), dimethyl isosorbide(l,4:3,6-dianhydro-2,5-dimethyl-D- glucitol), glycofurol(tetiahydrofi ⁇ rfuryl alcohol polyethylene glycol ether), propylene glycol(l,2-dihydroxypropane), propylene carbonate(4-methyl-2- oxo-l,3-dioxolane), solutol(macrogol 15 hydroxystearate, BASF) and a mixture thereof, wherein transcutol is preferred.
  • Volatile solvent The volatile solvent employed during the manufacturing process, but not present in the final product, assists the dissolution of itraconazole by the action of the acidifying agent.
  • a non-toxic organic solvent such as an alcohol, e.g., ethanol, propanol and isopropanol, which can be easily volatilized at a temperature of less than 100 °C .
  • Surfactant The surfactant used in the present invention assists the formulation of a uniform emulsion of an oil and hydrophilic components, and keeps the emulsion stable during storage.
  • surfactant examples include: CD polyoxyethylene glycolated natural or hydrogenated vegetable oils such as polyoxyethylene glycolated natural or hydrogenated castor oil(Cremophor ® , BASF; HCO ® , Nikkol), polyoxyethylene-sorbitan-fatty acid esters wherein fatty acid is mono- or tri-lauric, palmitic, stearic or oleic acid(Tween , ICI), and (H) polyoxyethylene fatty acid esters such as polyoxyethylene stearic acid ester(Myrj, ICI).
  • Oil The oil component used in the present invention should be compatible with the surfactant and capable of forming a stable microemulsion in an aqueous medium.
  • the inventive composition is prepared by (a) dissolving itraconazole in a mixture of the acidifying agent, the amphiphilic additive and the volatile solvent, (b) dissolving the surfactant and the oil in the resulting solution, and (c) removing the volatile solvent from the resulting mixed solution.
  • the volatile solvent may be removed by the conventional method, e.g., by heating under the ambient pressure or a vacuum, preferably at a temperature ranging from 40 to 100 ° C, more preferably at a temperature ranging from 40 to 80 °C .
  • itraconazole, the acidifying agent, the amphiphilic additive, the volatile solvent, the surfactant and the oil are used in amounts corresponding to a weight ratio in the range of 1 : 0.5-15 : 0.5-20 : 0.5-20 : 0.5-15 : 0.5-15, preferably 1 : 1-10 : 1-15 : 1-15 : 1-10 : 1-10.
  • the final composition of the present invention with the absence of volatile solvent comprises itraconazole, the acidifying agent, the amphiphilic additive, the surfactant and the oil in a weight ratio in the range of 1 : 0.5-15 : 0.5-20 : 0.5-15 : 0.5-15, preferably 1 : 1-10 : 1-15 : 1-10 : 1-10.
  • the inventive composition may comprise pharmaceutically acceptable additives for oral administration such as anti-oxidants.
  • the pharmaceutical composition of the present invention may be formulated to obtain various pharmaceutical preparations, e.g., a powder, granule, tablet, coated preparation and liquid preparation, in accordance with any of the conventional procedures.
  • a hard capsule may be prepared by adding a lubricant and other pharmaceutical additives to the pharmaceutical composition, processing the mixture into a powder or granule and filling the powder or granule into a hard gelatin capsule; a tablet, by adding a suitable additive to the pharmaceutical composition and tableting the mixture; a liquid preparation, by dissolving the pharmaceutical composition in water; and a coated preparation, by coating a solution of the pharmaceutical composition on a sugar bead such as Non-pareil (Edward Mendell Co., UK).
  • the inventive itraconazole composition prepared is transparent and glassy, i.e., it has no fluidity, and has a high viscosity of at least 10,000 cps at
  • the high viscosity glassy composition is much more compact as compared with a conventional microemulsion composition.
  • the inventive composition has self-microemulsifying capability to form high stable and available microemulsion particles when orally administered in the body fluid.
  • the inventive composition can maintain a high and stable level of itraconazole dissolution rate even under a neutral or alkaline condition of pH 6.8 or higher, the itraconazole bioavailability thereof is little influenced by ingested food; the itraconazole bioavailabilities of the inventive composition before and after ingestion are the same, the ratio of AUC bef0re ingestion and AUC afte r ingestion being close to 1 (AUC : area under the curve of blood concentration), preferably 0.8 or higher.
  • AUC area under the curve of blood concentration
  • a hard capsule was prepared using the following ingredients: Quantityfaig/capsule Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 Cremophor ® EL 220 dl- ⁇ -tocopherol 60 (*not present in the final composition) Itraconazole was dissolved uniformly in a mixture of 85% phosphoric acid, transcutol and ethanol, and other ingredients were added thereto and dissolved. Then, the resulting mixture was concentrated while heating at 55 °C for 4 hrs to volatilize ethanol therefrom to obtain a viscous and transparent composition having no fluidity. The composition was filled into a hard capsule by the conventional method described in the General Preparation Rule of Korea Pharmacopoeia.
  • Example 2 Preparation of Soft Capsule
  • a soft capsule was prepared using the following ingredients: Quantityfmg/capsule) Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 150 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 80 Cremophor ® EL 200 dl- ⁇ -tocopherol 60 (*not present in the final composition) The procedure of Example 1 was repeated using the above ingredients to obtain a viscous and transparent composition having no fluidity. The composition was filled into a soft capsule by the conventional method described in the General Preparation Rule of Korea Pharmacopoeia.
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • Example 4 Preparation of Hard Capsule - ⁇ 3) A hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • Quantityfmg/capsule Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 200 Tween ® 20 80 dl- ⁇ -tocopherol 60 (*not present in the final composition)
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients: OuantitvCmg/capsule Itraconazole 50 Phosphoric acid 85% 200 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 150 Cremophor ® EL 150 dl- ⁇ -tocopherol 60 (*not present in the final composition)
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients: Quantity(mg/capsule Itraconazole 50 Phosphoric acid 85% 150 Ethanol 300* Transcutol 83 Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 Cremophor ® EL 220 dl- ⁇ -tocopherol 60 (*not present in the final composition)
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • Quantityfmg/capsule Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* Glycofiirol 83
  • Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 Cremophor ® EL 220 dl- ⁇ -tocopherol 60 (*not present in the final composition)
  • a hard capsule was prepared by the procedure of Example 1 using the following ingredients:
  • a hard capsule was prepared by the procedure of Example 1, except 12
  • amphiphilic additive transcutol
  • Quantityfaig/capsule Itraconazole 50 Phosphoric acid 85% 208 Ethanol 300* Polyoxyethylene-50-hydrogenated castor oil(HCO ® 50) 70 Cremophor EL 220 dl- ⁇ -tocopherol 60 (*not present in the final composition)
  • Example 1 The dissolution rates of itraconazole were determined for the inventive preparation of Example 1; the preparation of Comparative Example; Sporanox capsule; Sporanox tablet; and Sporanox liquid (Janssen Korea), in accordance with the dissolution test method II(paddle method) described in the General Tests chapter of Korean Pharmacopoeia under the conditions listed below:
  • Test apparatus Erweka DT80(Erweka, Germany)
  • Test solutions 900 ml of artificial gastric juice(pH 1.2) 900 ml of phosphate buffer(pH 6.8)
  • Temperature of test solutions 37 ⁇ 0.5 Rotation speed: 100 ⁇ 4 rpm
  • - detector UV 255 nm
  • Example 1 exhibits higher amounts of itraconazole dissolved than those of Comparative Example and the commercially available preparations at pH 1.2 or 6.8.
  • the result shows that, in pH 6.8, the itraconazole dissolution rate of the preparation of Example 1 is remarkably enhanced as compared with the commercially available preparations.
  • Test Example 2 In Vivo Absorption Test

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur une composition visqueuse et vitreuse pour administration orale comprenant de l'itraconazole, un acidifiant, un additif amphiphilique, un tensio-actif et une huile, et présentant une grande biodisponibilité in vivo de l'itraconazole, peu influencée par la nourriture ingérée.
EP04774524A 2003-09-09 2004-09-07 Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation Withdrawn EP1663231A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2003-0063147A KR100529766B1 (ko) 2003-09-09 2003-09-09 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법
PCT/KR2004/002264 WO2005023262A1 (fr) 2003-09-09 2004-09-07 Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation

Publications (2)

Publication Number Publication Date
EP1663231A1 true EP1663231A1 (fr) 2006-06-07
EP1663231A4 EP1663231A4 (fr) 2009-04-29

Family

ID=36096818

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04774524A Withdrawn EP1663231A4 (fr) 2003-09-09 2004-09-07 Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation

Country Status (10)

Country Link
EP (1) EP1663231A4 (fr)
JP (1) JP2007505103A (fr)
KR (1) KR100529766B1 (fr)
CN (1) CN100475211C (fr)
AU (1) AU2004270069B2 (fr)
BR (1) BRPI0414192A (fr)
CA (1) CA2538019C (fr)
IL (1) IL173743A (fr)
MX (1) MXPA06002239A (fr)
RU (1) RU2006111477A (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
CN104688536B (zh) * 2015-02-03 2016-06-08 常州制药厂有限公司 一种伊曲康唑制剂的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
KR20050026169A (ko) 2005-03-15
AU2004270069A1 (en) 2005-03-17
IL173743A0 (en) 2006-07-05
AU2004270069B2 (en) 2008-03-13
EP1663231A4 (fr) 2009-04-29
JP2007505103A (ja) 2007-03-08
BRPI0414192A (pt) 2006-10-31
MXPA06002239A (es) 2006-06-20
CN1849123A (zh) 2006-10-18
CA2538019C (fr) 2009-09-01
CN100475211C (zh) 2009-04-08
RU2006111477A (ru) 2006-08-27
KR100529766B1 (ko) 2005-11-17
CA2538019A1 (fr) 2005-03-17
IL173743A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
US6039981A (en) Antifungal oral composition containing itraconazole and process for preparing same
CA2145242C (fr) Preparation pharmaceutique orale
EP1109532B1 (fr) Composition orale de silybine sous forme de microemulsion
RU2140291C1 (ru) Фармацевтический состав для солюбилизации плохорастворимого активного агента в составе-носителе и способ его изготовления
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
MXPA05001350A (es) Composiciones farmaceuticas que comprenden ciclosporina para administracion oral.
MXPA05001352A (es) Formulacion farmaceutica que comprende ciclosporina, ester de glicol de propileno y agente tensoactivo no ionico.
WO2004012770A1 (fr) Compositions pharmaceutiques orales contenant de la cyclosporine
EP3854384A1 (fr) Formulation pharmaceutique comprenant de l'acétate d'abiratérone
US20050058670A1 (en) Oral itraconazole composition which is not affected by ingested food and process for preparing same
CA2538019C (fr) Composition orale d'itraconazole non affectee par la nourriture ingere et son procede de preparation
JP2006509785A (ja) ビフェニルジメチルジカルボン酸の経口用マイクロエマルション組成物
NZ545768A (en) Oral itraconazole composition which is not affected by ingested food and process for preparing same
AU762963B2 (en) Cyclosporin solution
KR100455216B1 (ko) 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
WO2007064084A1 (fr) Granules contenant du pranlukast et leurs procedes de preparation
KR101052947B1 (ko) 아젤라스틴 액상 제제
KR20050121497A (ko) 이트라코나졸의 경구투여용 조성물 및 그 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090331

17Q First examination report despatched

Effective date: 20090715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101026